Table 4 Risk for Predicting Acquisition of Multi-drug Resistant Pseudomonas aeruginosa

Co-occurring condition

Diabetes Mellitus

Araujo 2016 [12]

Non-MDR PA

OR 1.9907 (0.97,4.09); 0.0608

Procedure

Surgery

Cortes 2009 [22]

Control

OR 2.8 (0.7,11.7); 0.14

Mechanical ventilation

OR 12.2 (0.1,12.6); 0.014

Stay

Hospital

Ossa-Giraldo 2014 [19]

Susceptible PA

OR 1.03 (1.01,1.05); sig

ICU

Cortes 2009 [22]

Control

OR 1.2 (0.6,12.7); 0.91

ICU

Dantas 2014^a [15]

Resistant PA

OR 3.28 (NR); 0.02

Therapy

IIAT

Araujo 2016 [12]

Non-MDR PA

OR 3.0169 (1.72,5.31); 0.0001

Feeding

Parenteral feeding

Gomes 2012 [30]

Non-MDR PA

OR 10.7 (1.5,91.9); 0.018

Enteral feeding

Gomes 2012 [30]

Non-MDR PA

OR 14.9 (3.3,94.1); 0.003

Prior antibiotic use

Aminoglycoside

Neves 2010 [18]

Non-MDR PA

Correlation coefficient 0.31 (NR); 0.14

Aminoglycoside

Ossa-Giraldo 2014 [19]

Susceptible PA

OR 3.09 (1.26,7.58); NR

Carbapenem

Neves 2010 [18]

Non-MDR PA

Correlation coefficient 0.67 (NR); 0.01

Carbapenem

Araujo 2016 [12]

Non-MDR PA

OR 0.8928 (0.51,1.55); 0.6873

Quinolone

Neves 2010 [18]

Non-MDR PA

Correlation coefficient − 0.13 (NR); 0.57

Quinolone

Gomes 2012 [30]

Non-MDR PA

OR 8.9 (1.6,66.4); 0.013

3rd-generation Cephalosporin

Neves 2010 [18]

Non-MDR PA

Correlation coefficient 0.16 (NR); 0.31

>2antimicrobials for > 48 h in prior 30 d

Ossa-Giraldo 2014 [19]

Susceptible PA

OR 4.4 (1.1,17.65); NR

Any

Cortes 2009 [22]

Control

OR 2.7 (1.2125); 0.19

Sex

Female

Ossa-Giraldo 2014 [19]

Susceptible PA

OR 2.31 (1.02,5.2); sig

Source of infection

Respiratory tract source of bacteremia

Dantas 2014^a [15]

Resistant PA

5.83 (NR); 0.02